{
    "name": "relugolix",
    "comment": "Rx",
    "other_names": [
        "Orgovyx"
    ],
    "classes": [
        "Antineoplastics",
        "GNRH Antagonists"
    ],
    "source": "https://reference.medscape.com/drug/orgovyx-relugolix-4000119",
    "pregnancy": {
        "common": [
            "Based on findings in animals and mechanism of action, can cause fetal harm and loss of pregnancy when administered to pregnant females",
            "Human data are unavailable"
        ],
        "specific": [
            {
                "type": "Animal studies",
                "description": [
                    "Administration to pregnant rabbits during organogenesis caused embryofetal lethality at maternal exposures that were 0.3 times the human exposure at the recommended dose of 120 mg daily based on AUC"
                ]
            },
            {
                "type": "Contraception",
                "description": [
                    "Males with female partners of reproductive potential: Use effective contraception during treatment and for 2 weeks after last dose"
                ]
            },
            {
                "type": "Infertility",
                "description": [
                    "Based on findings in animals and mechanism of action, may impair fertility in males of reproductive potential"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Data are unavailable on presence in human milk, effects on breastfed children, or effects on milk production",
            "Relugolix and/or its metabolites were present in milk of lactating rats at concentrations up to 10-fold higher than in plasma at 2 hr post dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Based animal studies and mechanism of action, fetal harm may occur ",
                "Therapy suppresses pituitary gonadal system; results of diagnostic tests conducted during and after treatment may be affected; monitor therapeutic effect of relugolix by measuring serum concentrations of prostate specific antigen (PSA) periodically; if PSA increases, measure serum testosterone concentrations",
                "Hypersensitivity reactions, including pharyngeal edema and other serious cases of angioedema, reported; advise patients who experience any symptoms of hypersensitivity to temporarily discontinue therapy and promptly seek medical care; discontinue therapy for severe hypersensitivity reactions and manage as clinically indicated"
            ],
            "specific": [
                {
                    "type": "QT/QTc interval prolongation",
                    "description": [
                        "Androgen deprivation therapy may prolong QT/QTc interval",
                        "Consider benefits and risks in patients with congenital long QT syndrome, congestive heart failure, or frequent electrolyte abnormalities, and those taking drugs known to prolong QT interval ",
                        "Correct electrolyte abnormalities",
                        "Consider periodic ECG and electrolyte monitoring"
                    ]
                },
                {
                    "type": "Drug interaction overview",
                    "description": [
                        "CYP enzymes: Substrate of CYP3A (primarily) and CYP2C8 (minor)",
                        "Transporter systems: Substrate of P-gp; inhibitor of BCRP and P-gp",
                        "P-gp inhibitors",
                        "Avoid coadministration",
                        "Coadministration increases relugolix AUC and peak plasma concentration; if unable to avoid, adjust time between dosing relugolix and the P-gp inhibitor ",
                        "Combined P-gp and strong CYP3A inducers",
                        "Avoid coadministration",
                        "Coadministration decreases relugolix AUC and peak plasma concentration; if unable to avoid, adjust relugolix dose "
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gallium Ga 68 PSMA-11",
            "description": {
                "common": "relugolix will decrease the level or effect of gallium Ga 68 PSMA-11 by  unspecified interaction mechanism. Modify Therapy/Monitor Closely. Androgen deprivation therapy and other therapies targeting the androgen pathway may result in changes in the uptake of gallium Ga 68 PSMA-11 in prostate cancer. The effect of ADT on the performance of gallium Ga 68 PSMA-11 is unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Hot flush",
            "percent": "54"
        },
        {
            "name": "Glucose increased",
            "percent": "44"
        },
        {
            "name": "Triglycerides increased",
            "percent": "35"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "30"
        },
        {
            "name": "Hemoglobin decreased",
            "percent": "28"
        },
        {
            "name": "ALT increased",
            "percent": "27"
        },
        {
            "name": "Fatigue",
            "percent": "26"
        },
        {
            "name": "AST increased",
            "percent": "18"
        },
        {
            "name": "Diarrhea",
            "percent": "12"
        },
        {
            "name": "Constipation",
            "percent": "12"
        },
        {
            "name": "Increased weight",
            "percent": "10"
        },
        {
            "name": "Insomnia",
            "percent": "10"
        },
        {
            "name": "Gynecomastia",
            "percent": "10"
        },
        {
            "name": "Hyperhidrosis",
            "percent": "10"
        },
        {
            "name": "Depression",
            "percent": "10"
        },
        {
            "name": "Decreased libido",
            "percent": "10"
        },
        {
            "name": "Glucose increased",
            "percent": "2.9"
        },
        {
            "name": "Triglycerides increased",
            "percent": "2"
        },
        {
            "name": "Musculoskeletal pain",
            "percent": "1.1"
        },
        {
            "name": "Hot flush",
            "percent": null
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "ALT increased",
            "percent": null
        },
        {
            "name": "Hemoglobin increased",
            "percent": null
        }
    ]
}